Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action.[A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568]
Synonyms
4-(6-Methoxy-2-naphthyl)-2-butanone
Nabumetonum
Nabumeton
Nabumetone
4-(6-Methoxy-2-naphthalenyl)-2-butanone
Nabumetona
Nabumétone
Brand Names
NuDroxiPAK N-500
Relafen DS
Nabumetone
Nabumetone 1000 mg
Relafen Tablets 500mg
Teva-nabumetone
Nabumetone 500 mg
PMS-nabumetone
Nabumetone 750 mg
Relafen Tablets 750mg
Nabumetone-500
Sandoz Nabumetone
Relafen
Mylan-nabumetone
Indication
**Indicated** for:[label] 1) Symptomatic relief in rheumatoid arthritis. 2) Symptomatic relief in osteoarthritis.
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
